


# Opportunities and Challenges for innovation & Dealing with the Clinical Backlog – Post Covid

SEHTA 2021 MedTech Expo & Conference



**Professor Reza Razavi Vice Principal/Vice-President (Research) King's College London**  
**Consultant Cardiologist and Non-exec Director Guy's and St Thomas' NHS FT**  
**Director of UKRI London Medical imaging & AI Centre for Value Based Healthcare**



# Covid pandemic has left a burning platform for the NHS!!

**NUMBER OF PEOPLE LEFT WAITING OVER A YEAR FOR ROUTINE TREATMENT IN ENGLAND**




**NUMBER OF PEOPLE LEFT WAITING OVER 18 WEEKS FOR ROUTINE TREATMENT IN ENGLAND**




# Covid pandemic has left a burning platform for the NHS!!

## PATIENTS IN ENGLAND WAITING 1+ YEARS FOR ROUTINE SURGERY



## Numbers on NHS waiting lists in England now exceed 5 million

Referred but waiting for treatment, by length of wait (millions)



Source: NHS England

© FT



# Examples of innovations being developed by KCL and GST & KCH at London Medical Imaging & AI Centre for Value based Healthcare that could help!

- Triage tool to reduce reporting backlog of brain MRIs - Dr Tom Booth
- Triage tool to help with prostate cancer 28-day diagnostic pathway - Prof Seb Ourselin
- Clinical decision support for patients having cardiac MRIs – Dr Andy King
- Scanning support for antenatal fetal abnormality screening – Prof Jo Hajnal



# Triage tool to reduce reporting backlog of brain MRIs


- Growing demand for head MRI examinations + global shortage of radiologists = increase in the time taken to report head MRI scans
- In the UK, reporting times for out-patient brain MRI scans have increased every year since 2012
- Currently, 2% of departments meeting reporting requirements within contracted hours
- ~ 330,000 patients waiting > 30 days to receive radiology report
- These figures were pre-COVID but have now deteriorated further
- For many neurological conditions (e.g., acute stroke, brain tumour, aneurysm...), this delay is leading to poor patient outcomes and increased mortality

Clinical radiology  
UK workforce census 2020 report



# Triage tool to reduce reporting backlog of brain MRIs


- A solution to reduce reporting times for abnormal scans is to develop a triage tool to identify abnormalities at the time of imaging, and prioritize the reporting of these scans
- Computer vision convolutional neural networks show promise for this task
- However, a bottleneck to model development is the difficulty obtaining large, clinically-representative, labelled datasets



# Triage tool to reduce reporting backlog of brain MRIs


- 54,115 adult ( $\geq 18$  years) MRI head scans performed at King's College Hospital (KCH) and Guy's and St Thomas' Hospital (GSTT) between 2008-2019 were obtained
- The corresponding radiology reports produced by expert neuroradiologists were also obtained
- Using a validated NLP report classifier, each MRI scan was labelled 'normal' or 'abnormal'
- This labelled dataset was then used to train a computer vision model to distinguish 'normal' or 'abnormal' scans

## Archived MRI examinations




Radiology reports

## Deep learning radiology report classifier



Normal examination?


## Labelled examinations



# Triage tool to reduce reporting backlog of brain MRIs

- Accurate classification on a test set of 800 images manually labelled by two neuroradiologists (despite 90 classes of morphologically distinct abnormalities)
- Best model (AUC = 0.943) trained and tested on scans pooled from KCH + GSTT
- Models generalised between hospitals ( $\Delta \text{AUC} \leq 0.02$ )


Train		KCH			GSTT			Pooled		
Test		KCH	GSTT	Pooled	KCH	GSTT	Pooled	KCH	GSTT	Pooled
Model	Baseline	0.921	0.909	0.915	0.903	0.918	0.912	0.925	0.920	0.922
	Noise-corrected	0.941	0.925	0.933	0.929	0.931	0.930	0.946	0.939	0.943






# Triage tool to reduce reporting backlog of brain MRIs

- Retrospective simulation study performed using data from 1/1/18–31/12/18
- Reduction in abnormal reporting times (28-14 days GSTT, 9-5 days KCH)



# Triage tool to help with prostate cancer 28-day diagnostic pathway




# Triage tool to help with prostate cancer 28-day diagnostic pathway

## Clinical challenge #1:

- Rising case incidence: 12% growth in cases projected in the UK between 2014 and 2035<sup>1</sup>.
- Shortfall of clinical radiology consultants: 33% shortfall in the UK in 2020<sup>2</sup>.
- MRI-based screening recommended by EAU-EANM-ESTRO-ESUR-SIOG guidelines<sup>3</sup>.

## Solution: AI-driven triage: Patient Classification Framework (PCF)<sup>4</sup>



## Patient classification performance:

- Comparable sensitivity and specificity to an experienced radiologist (>10 years)<sup>4</sup>.

## Intended clinical use:

- For use following mpMRI collection, and prior to clinical read.
- **Rule out** lowest risk patients who can avoid clinical read / **prioritise** highest risk patients.

## Steps to clinical adoption:

- Multicenter validation study.
- Deployment & prospective validation.

<sup>1</sup>[www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer](http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer)

<sup>2</sup>NHS Cancer Clinical Radiology UK workforce census 2020 report

<sup>3</sup>Mottet, N. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. *Eur. Urol.* **2021**, 79, 243–262.


<sup>4</sup>Mehta, P. et al. Computer-aided diagnosis of prostate cancer using multiparametric MRI and clinical features: A patient-level classification framework. *Med. Image Anal.* **2021**, 73, 102153.

# Triage tool to help with prostate cancer 28-day diagnostic pathway

## Clinical challenge #2:

- ~10% of clinically significant cancers missed on mpMRI<sup>1</sup>.
- ~50% men undergo an unnecessary biopsy<sup>1</sup>.
- High inter-reader variability<sup>1</sup>.

## Solution: AutoProstate: A Deep Learning-Powered Framework for Automated MRI-Based Prostate Cancer Assessment<sup>2</sup>.



## Standalone performance:

- Improved prostate volume and prostate-specific antigen density estimation.
- Matched experienced radiologist (>10 years) detection sensitivity.

## Intended clinical use:

- **Companion system** for radiologists to improve diagnostic accuracy / reduce variability in diagnosis.

## Steps to clinical adoption:

- Multicenter validation study.
- Deployment & prospective validation.

<sup>1</sup>Ahmed, H.U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. *Lancet* 2017, 389, 815–822.

<sup>2</sup>Mehta, P. et al. AutoProstate: A Deep Learning-Powered Framework for Automated MRI-Based Prostate Cancer Assessment. *Under review*.

# Triage tool to help with prostate cancer 28-day diagnostic pathway

	T2WI	ADC Map	Computed b2000 DWI	Ground-Truth (overlaid on T2WI)	Probability Map (overlaid on T2WI)	Segmentation (overlaid on T2WI)
Patient A						
Patient B						
Patient C						
Patient D						
Patient E						

AutoProstate clinically significant prostate cancer lesion segmentations


### Web-Hosted Tool Built Using Streamlit

Select Patient: Anon

**CNN Output:**


Select Slice (Transverse):  1 / 28

Transverse




Select Slice (Frontal):  1 / 256

Frontal



Select Slice (Sagittal):  1 / 256

Sagittal



### AutoProstate Report

**Patient Details**

Patient Name: Anon	Date of Birth: 22/09/1948	Age: 64 years
Hospital Number: unknown	Scan Date: 14/06/2012	PSA: 10.53 ng/ml

**Prostate Size and PSA Density**

Transverse: 5.42 cm	Prostate Volume: 36.24 cm <sup>3</sup>	PSA Density: 0.29 ng/ml <sup>2</sup>
Anterior-Posterior: 3.78 cm	Peripheral Zone Volume: 20.98 cm <sup>3</sup>	
Cranio-Caudal: 3.90 cm	Central Gland Volume: 15.26 cm <sup>3</sup>	

**Clinically Significant Lesion Candidates**

Show Lesions

LESION 1: Probability of CSPCa = 95% || Centroid Slice = 12 || Centroid Zone = CG || Centroid Region = Apex || Min ADC = 619 x 10<sup>-6</sup> mm<sup>2</sup>/s || Volume = 2.14 cm<sup>3</sup> || Extra-Capsular? = True

--	--	--	--

LESION 2: Probability of CSPCa = 46% || Centroid Slice = 18 || Centroid Zone = PZ || Centroid Region = Base || Min ADC = 613 x 10<sup>-6</sup> mm<sup>2</sup>/s || Volume = 0.34 cm<sup>3</sup> || Extra-Capsular? = True

--	--	--	--

LESION 3: Probability of CSPCa = 7% || Centroid Slice = 15 || Centroid Zone = CG || Centroid Region = Midgland || Min ADC = 1070 x 10<sup>-6</sup> mm<sup>2</sup>/s || Volume = 0.09 cm<sup>3</sup> || Extra-Capsular? = False

--	--	--	--


**Findings Summary**

Anon is a 64 year old male with PSA equal to 10.53 ng/ml, who was scanned on 14/06/2012. AutoProstate estimates the prostate volume to be 36.24 cm<sup>3</sup>. Therefore, PSA density is estimated to be 0.29 ng/ml<sup>2</sup>. Patient has N=3 predicted CSPCa lesions. The index lesion has a probability of CSPCa equal to 95%, is located in the Apex CG, has a minimum ADC value equal to 619 x 10<sup>-6</sup> mm<sup>2</sup>/s, and has an approximate volume equal to 2.14 cm<sup>3</sup>. Extra-capsular extension is observed for N=2 of the predicted CSPCa lesions.

AutoProstate report for 64-year-old man with a Gleason score 3+4 (significant) tumour in the transition zone


# Clinical decision support for patients having cardiac MRIs

---




# Clinical decision support for patients having cardiac MRIs


## Full CMR exam



## Step1: Class identification



## Step 2: Quality control



## Step 1 and 2: DenseNet classifier


- UKBB & GSTT data
- Validated against experienced CMR cardiologist
- Validation on 400 clinical exams

2-chamber		
BACC	SEN	SPE
90.6	89.7	91.5
3-chamber		
BACC	SEN	SPE
89.2	93.2	85.3
4-chamber		
BACC	SEN	SPE
91.6	89.2	94.5



# Clinical decision support for patients having cardiac MRIs

nnU-Net framework to segment the short axis and long axis CMR sequences


## Input images




## Pre-processing



## Training (learning) U-Net





## Segmentation



## Cardiac function assessment (DXX)

LV EDV (mL)	170	RV EDV (mL)	178
LV ESV (mL)	75	RV ESV (mL)	83
LV SV (mL)	95	RV SV (mL)	95
LV EF (%)	56	RV EF (%)	47
LV peak ejection rate (mL/s)	473	LV peak circumferential strain (%)	-21
LV peak filling rate (mL/s)	408	LV peak radial strain (mL/s)	+51
LV peak atrial filling rate (mL/s)	155	LV peak 2ch long. strain (%)	-19
LV atrial contribution (mL)	24	LV peak 2ch long. strain (%)	-18





# Clinical decision support for patients having cardiac MRIs


Clinicians use prior knowledge

- Physiological principals
- Expected behaviour





Contraction-relaxation follows certain principles

- Volume Curve
- Strain curves


*Can we use this knowledge to detect potential errors?*



Cardiac Volumes



# Clinical decision support for patients having cardiac MRIs



## LV RV segmentation algorithm

- GSTT & UKBB data
- Human-level accuracy<sup>1</sup>
- Limits of agreement vs. man  $\pm 6-7$  mL

## CMR Feature Tracking


- Limits of agreement vs. cvi42:  $\pm 4-7\%$

## Total image-processing pipeline

- Validated against experienced CMR cardiologist
- 700 cases (500 healthy 200 ischemic CM)
- Sensitivity of detecting errors
  - Volumes 94.99%
  - Strain 93.21%


# Scanning support for antenatal fetal abnormality screening

Ultrasound-based screening programmes aim to detect fetal anomalies before babies are born



# Scanning support for antenatal fetal abnormality screening


- However these screening programmes currently fail to achieve universal detection
- In the UK, *half* of babies undergoing surgery for major heart disease are diagnosed only after they are born
- Can AI help improve this?



# Scanning support for antenatal fetal abnormality screening


- Several AI models combined into a single, clinically usable tool
- Analyses the stream of ultrasound video in real-time, with feedback to the sonographer

Clinical tool:



# Scanning support for antenatal fetal abnormality screening

Laptop running AI models




Additional monitor giving real-time feedback to sonographers

Standard clinical ultrasound machine

# Scanning support for antenatal fetal abnormality screening

- 23 pregnant women with healthy fetuses scanned with both AI-assisted and standard manual ultrasound techniques
- Removes need to pause, measure, save images- AI **completely disrupts** the way the scan is performed
- **Automatic report** means that sonographers have a chance to review and assess the automatically saved images and measurements:



# Scanning support for antenatal fetal abnormality screening

- **Significant time savings**- average AI scan 14 minutes vs 22 minutes for standard manual scan: more time to focus on important aspects
- Automatic measurement of fetal body size **highly accurate and reproducible**: frees sonographer to concentrate on detecting disease
- Future work: addition of AI to automatically detect fetal disease



# Conclusion

- Covid-19 pandemic has left a very large delivery problem for the NHS and **accelerated deployment of healthcare technologies** including AI will need to be part of the solution
- Making **NHS Data available for AI tool development at scale**, “bringing the algorithms to the data” and **empowering NHS Trusts to deploy AI tools** into their day-to-day workflow core to the mission of the London AI centre for Value Based Healthcare
- Enabling **industry, NHS, academic teams to create innovate products** and scale them in the NHS and internationally
- Many clinical pathways are being addressed with a focus on value – **improving outcomes and reducing costs** with strong engagement with NHS commissioners and health economics
- The big challenge remains the readiness of the wider NHS to accept innovative technology into it’s clinical workflow but much is being done to address this challenge.

